UPDATED Jan 09, 2026
Discover U.S. Pharmaceuticals & Biotech Growth Stocks that are on the NYSE and NASDAQ. Sorted by forecasted growth, these Pharmaceuticals & Biotech Stocks have higher than expected earnings or sales growth compared to other companies.
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
SNDL | US$1.66 | -4.6% | -9.8% | US$422.3m | US$4.81 | PB0.5x | E157.8% | n/a | ||
IXHL | US$0.40 | 1.5% | -78.6% | US$137.1m | n/a | PS11425.4x | E126.5% | n/a | ||
TLRY | US$9.18 | -5.6% | -25.4% | US$1.1b | US$12.81 | PS1.3x | E118.7% | n/a | ||
AVTR | US$12.41 | 8.3% | -42.7% | US$8.2b | US$13.04 | PS1.3x | E113.7% | n/a | ||
HBIO | US$0.63 | -3.3% | -66.8% | US$29.1m | US$2.00 | PB2x | E111.3% | n/a | ||
ORGO | US$4.21 | -9.2% | 39.9% | US$534.3m | US$8.50 | PS1.1x | E104.2% | n/a | ||
HYPD | US$3.30 | -7.8% | -61.8% | US$28.2m | US$5.88 | PS78.1x | E97.8% | n/a | ||
AMRN | US$15.82 | 15.3% | 43.3% | US$341.0m | US$12.00 | PS1.5x | E94.5% | n/a | ||
EBS | US$12.96 | 3.6% | 31.2% | US$701.7m | US$13.50 | PE9x | E91.3% | n/a | ||
VTRS | US$12.76 | 2.4% | 9.3% | US$14.5b | US$12.78 | PS1x | E85.6% | 3.8% | ||
AYTU | US$2.64 | -4.7% | 51.7% | US$27.1m | US$9.33 | PB1.2x | E83.6% | n/a | ||
SBFM | US$1.33 | 3.9% | -54.6% | US$6.7m | US$6.00 | PB0.3x | E83.5% | n/a | ||
SNOA | US$3.65 | 0.3% | 40.4% | US$6.4m | US$13.40 | PB1.6x | E83.1% | n/a | ||
MDXH | US$3.26 | -5.0% | 64.6% | US$161.9m | US$7.04 | PS1.6x | E81.2% | n/a | ||
AMRX | US$12.96 | 2.4% | 62.6% | US$4.1b | US$14.40 | PE690.5x | E79.9% | 0% | ||
JAGX | US$1.05 | 5.3% | -95.8% | US$4.9m | US$25.50 | PB1.5x | E78.1% | n/a | ||
BRKR | US$54.46 | 13.2% | -10.4% | US$8.0b | US$53.14 | PS2.4x | E73.4% | 0.4% | ||
CLGN | US$1.47 | -0.7% | -65.0% | US$18.4m | US$11.56 | PS7.6x | E73.0% | n/a | ||
HYFT | US$2.72 | 34.7% | 414.7% | US$127.0m | US$4.00 | PS6.6x | E72.7% | n/a | ||
OGEN | US$0.83 | -0.5% | -91.9% | US$3.5m | US$2.00 | PB0.4x | E69.8% | n/a | ||
SRRA | US$54.99 | 0.06% | 179.4% | US$1.3b | US$55.00 | PB5.1x | E69.5% | n/a | ||
PLX | US$2.07 | 19.0% | -8.8% | US$160.8m | US$11.00 | PE30.9x | E68.7% | n/a | ||
MYGN | US$6.58 | 7.2% | -55.6% | US$611.5m | US$8.12 | PB1.6x | E68.5% | n/a | ||
EXAS | US$102.11 | 0.4% | 80.7% | US$19.3b | US$104.56 | PS6.3x | E68.1% | n/a |